LaShonda Y Spencer1, Shawna Christiansen, Chia-Hao H Wang, Wendy J Mack, Mary Young, Howard D Strickler, Kathryn Anastos, Howard Minkoff, Mardge Cohen, Ruth M Geenblatt, Roksana Karim, Eva Operskalski, Toni Frederick, James D Homans, Alan Landay, Andrea Kovacs. 1. *Maternal, Child and Adolescent Center for Infectious Diseases and Virology, Department of Pediatrics, Division of Infectious Disease, University of Southern California Keck School of Medicine, Los Angeles, CA; †Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA; ‡Department of Medicine, Division of Infectious Diseases, Georgetown School of Medicine, Washington, DC; §Departments of Medicine and Epidemiology and Population Health, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx NY; ‖Department of Obstetrics and Gynecology, Maimonides Medical Center and SUNY Downstate, Brooklyn, NY; ¶Departments of Medicine, Rush University and Cook County Bureau of Health, Chicago, IL; #Department of Clinical Pharmacology, University of California San Francisco School of Pharmacy, San Francisco, CA; **Department of Immunology and Microbiology, Rush University Medical Center, Chicago, IL.
Abstract
BACKGROUND: Plasma HIV RNA is the most significant determinant of cervical HIV shedding. However, shedding is also associated with sexually transmitted infections (STIs) and cervical inflammation. The mechanism by which this occurs is poorly understood. There is evidence that systemic immune activation promotes viral entry, replication, and HIV disease progression. We hypothesized that systemic immune activation would be associated with an increase in HIV genital shedding. METHODS: Clinical assessments, HIV RNA in plasma and genital secretions, and markers of immune activation (CD38(+)DR(+) and CD38(-)DR(-)) on CD4(+) and CD8(+) T cells in blood were evaluated in 226 HIV+ women enrolled in the Women's Interagency HIV Study. There were 569 genital evaluations of which 159 (28%) exhibited HIV RNA shedding, defined as HIV viral load >80 copies per milliliter. We tested associations between immune activation and shedding using generalized estimating equations with logit link function. RESULTS: In the univariate model, higher levels of CD4(+) and CD8(+) T-cell activation in blood were significantly associated with genital tract shedding. However, in the multivariate model adjusting for plasma HIV RNA, STIs, and genital tract infections, only higher levels of resting CD8(+) T cells (CD38(-)DR(-)) were significantly inversely associated with HIV shedding in the genital tract (odds ratios = 0.44, 95% confidence interval: 0.21 to 0.9, P = 0.02). CONCLUSIONS: The association of systemic immune activation with genital HIV shedding is multifactorial. Systemic T-cell activation is associated with genital tract shedding in univariate analysis but not when adjusting for plasma HIV RNA, STIs, and genital tract infections. In addition, women with high percentage of resting T cells are less likely to have HIV shedding compared with those with lower percentages. These findings suggest that a higher percentage of resting cells, as a result of maximal viral suppression with treatment, may decrease local genital activation, HIV shedding, and transmission.
BACKGROUND: Plasma HIV RNA is the most significant determinant of cervical HIV shedding. However, shedding is also associated with sexually transmitted infections (STIs) and cervical inflammation. The mechanism by which this occurs is poorly understood. There is evidence that systemic immune activation promotes viral entry, replication, and HIV disease progression. We hypothesized that systemic immune activation would be associated with an increase in HIV genital shedding. METHODS: Clinical assessments, HIV RNA in plasma and genital secretions, and markers of immune activation (CD38(+)DR(+) and CD38(-)DR(-)) on CD4(+) and CD8(+) T cells in blood were evaluated in 226 HIV+ women enrolled in the Women's Interagency HIV Study. There were 569 genital evaluations of which 159 (28%) exhibited HIV RNA shedding, defined as HIV viral load >80 copies per milliliter. We tested associations between immune activation and shedding using generalized estimating equations with logit link function. RESULTS: In the univariate model, higher levels of CD4(+) and CD8(+) T-cell activation in blood were significantly associated with genital tract shedding. However, in the multivariate model adjusting for plasma HIV RNA, STIs, and genital tract infections, only higher levels of resting CD8(+) T cells (CD38(-)DR(-)) were significantly inversely associated with HIV shedding in the genital tract (odds ratios = 0.44, 95% confidence interval: 0.21 to 0.9, P = 0.02). CONCLUSIONS: The association of systemic immune activation with genital HIV shedding is multifactorial. Systemic T-cell activation is associated with genital tract shedding in univariate analysis but not when adjusting for plasma HIV RNA, STIs, and genital tract infections. In addition, women with high percentage of resting T cells are less likely to have HIV shedding compared with those with lower percentages. These findings suggest that a higher percentage of resting cells, as a result of maximal viral suppression with treatment, may decrease local genital activation, HIV shedding, and transmission.
Authors: A Kovacs; S S Wasserman; D Burns; D J Wright; J Cohn; A Landay; K Weber; M Cohen; A Levine; H Minkoff; P Miotti; J Palefsky; M Young; P Reichelderfer Journal: Lancet Date: 2001-11-10 Impact factor: 79.321
Authors: Alan Landay; Lorie Benning; James Bremer; Barbara Weiser; Harold Burger; Marek Nowicki; Andrea Kovacs Journal: J Infect Dis Date: 2003-07-01 Impact factor: 5.226
Authors: J Kreiss; D M Willerford; M Hensel; W Emonyi; F Plummer; J Ndinya-Achola; P L Roberts; J Hoskyn; S Hillier; N Kiviat Journal: J Infect Dis Date: 1994-12 Impact factor: 5.226
Authors: G U Natividad-Villanueva; E Santiago; R M Manalastas; H W Brown; J Ingersoll; A M Caliendo; K H Mayer; S Cu-Uvin Journal: Int J STD AIDS Date: 2003-12 Impact factor: 1.359
Authors: Josè Ramòn Fiore; Barbara Suligoi; Annalisa Saracino; Mariantonietta Di Stefano; Roberto Bugarini; Achiropita Lepera; Anna Favia; Laura Monno; Gioacchino Angarano; Giuseppe Pastore Journal: AIDS Date: 2003-10-17 Impact factor: 4.177
Authors: Marta Bull; Caroline Mitchell; Jaime Soria; Sheila Styrchak; Corey Williams; Joan Dragavon; Kevin J Ryan; Edward Acosta; Frankline Onchiri; Robert W Coombs; Alberto La Rosa; Eduardo Ticona; Lisa M Frenkel Journal: J Infect Dis Date: 2020-08-04 Impact factor: 5.226
Authors: Caroline C King; Sascha R Ellington; Nicole L Davis; Robert W Coombs; Maria Pyra; Ting Hong; Nelly Mugo; Rena C Patel; Jairam R Lingappa; Jared M Baeten; Athena P Kourtis Journal: J Infect Dis Date: 2017-12-19 Impact factor: 5.226
Authors: Kerry Murphy; Marla J Keller; Kathryn Anastos; Shada Sinclair; J Cooper Devlin; Qiuhu Shi; Donald R Hoover; Brian Starkman; Jamie McGillick; Caroline Mullis; Howard Minkoff; Maria Gloria Dominguez-Bello; Betsy C Herold Journal: PLoS One Date: 2019-04-26 Impact factor: 3.752
Authors: Joan T Price; Winifreda M Phiri; Bethany L Freeman; Bellington Vwalika; Jennifer Winston; Chileshe M Mabula-Bwalya; Helen B Mulenga; Jeffrey S A Stringer Journal: PLoS One Date: 2020-01-29 Impact factor: 3.240
Authors: Joan T Price; Katie R Mollan; Nurain M Fuseini; Bethany L Freeman; Helen B Mulenga; Amanda H Corbett; Bellington Vwalika; Jeffrey S A Stringer Journal: Pilot Feasibility Stud Date: 2017-07-18